CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,500 enrolled
Drug / intervention
Dexmedetomidine supplemented morphine analgesia +1 moredrug
Likely dose
Dexmedetomidine supplemented morphine analgesia 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03012984
NCT03012984N/ACompleted
CompareCT.gov

Impact of Dexmedetomidine Supplemented Analgesia on Incidence of Delirium in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial

Peking University First Hospital·interventional·Posted Jan 6, 2017·Updated Jan 8, 2026

In Brief

A clinical study evaluating Dexmedetomidine supplemented morphine analgesia and Morphine analgesia for Elderly and 5 related conditions. Completed, enrolled 1,500 participants across 12 sites.

Detailed Summary

Delirium is a frequently occurred cerebral complication in elderly patients after surgery, and its occurrence is associated with worse outcomes. Sleep disturbances is considered to be one of the most important risk factors of postoperative delirium. Previous studies showed that, for elderly patients admitted to the ICU after surgery, low-dose dexmedetomidine infusion improved the quality of sleep and decreased the incidence of delirium. The investigators hypothesize that, for elderly patients after cancer surgery, dexmedetomidine supplemented analgesia can also decrease the incidence of delirium, possibly by improving sleep quality. The purpose of this multicenter, randomized controlled trial is to investigate the impact of dexmedetomidine supplemented analgesia on the incidence of delirium in elderly patients after cancer surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElderly, Surgery, Analgesia, Dexmedetomidine, Complication, Postoperative, Delirium
CountriesChina
CollaboratorsAffiliated Hospital of Hebei University, Qingdao Municipal Hospital, The Second Affiliated Hospital of Air Force Military Medical University, Peking University International Hospital, Guizhou Provincial People's Hospital, The Third Xiangya Hospital of Central South University, Shanxi Province Cancer Hospital, Tianjin Hospital of ITCWM-Nankai Hospital, Chongqing University Fuling Hospital, The Third Central Hospital of Tianjin, Xiyuan Hospital of China Academy of Chinese Medical Sciences

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 6, 2017
Enrollment StartJan 6, 2017
Primary CompletionMay 12, 2022
Study CompletionJun 11, 2022
TodayJul 1, 2026
Enrollment to primary: 5.4 yearsPosted 9.5 years ago

Interventions

Dexmedetomidine supplemented morphine analgesiadrug

Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.

Morphine analgesiadrug

Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.